Biogen (NASDAQ: BIIB) — Perfil da empresa, notícias e dados financeiros
Biogen develops therapies for neurological diseases, including multiple sclerosis and Alzheimer's treatments.
Biogen
Biogen is a global biotechnology company specializing in the discovery, development, and delivery of therapies for neurological, neurodegenerative, rare, and autoimmune diseases. Headquartered in Cambridge, Massachusetts, the company focuses on serious conditions such as multiple sclerosis, Alzheimer's disease, spinal muscular atrophy, amyotrophic lateral sclerosis, Friedreich's ataxia, and postpartum depression. Its portfolio includes prescription biopharmaceuticals, monoclonal antibodies, gene-silencing therapies, and biosimilar products. Biogen maintains international headquarters in Baar, Switzerland, alongside commercial footprint, research facilities, and manufacturing sites across North America, Europe, Asia-Pacific, Latin America, and the Middle East.
Resumo
Operações
Produtos e/ou serviços de Biogen
- Multiple Sclerosis Therapies: Commercialization of oral, injectable, and infusion prescription therapies designed to reduce relapse rates and slow disability progression in adults diagnosed with relapsing forms of multiple sclerosis across major global healthcare markets.
- Spinal Muscular Atrophy Treatments: Delivery of intrathecally administered antisense oligonucleotide medications that target SMN2 pre-mRNA splicing to treat pediatric and adult patients affected by spinal muscular atrophy in commercial markets worldwide.
- Alzheimer's Disease Treatments: Development and commercial distribution of humanized monoclonal antibodies targeting amyloid-beta soluble aggregates and protofibrils, engineered to slow cognitive and functional decline in early-stage Alzheimer's disease patients.
- Rare Disease Therapies: Production and supply of targeted small-molecule and oligonucleotide therapeutics for neurodegenerative rare conditions, including Friedreich ataxia and superoxide dismutase 1 mutation-associated amyotrophic lateral sclerosis.
- Neuropsychiatry Therapies: Commercialization of oral neuroactive steroid positive allosteric modulators of GABAA receptors prescribed for the treatment of postpartum depression in adult female patients across clinical healthcare settings.
- Biosimilars & Biologics Manufacturing: Manufacturing and distribution of anti-TNF biosimilar monoclonal antibodies for inflammatory diseases, alongside specialized biopharmaceutical contract manufacturing services for external corporate partners through biologics production facilities.
equipe executiva do Biogen
- Christopher A. ViehbacherPresident, CEO & Director
- Robin C. KramerExecutive VP & CFO
- Nicole MurphyExecutive VP and Head of Pharmaceutical Operations & Technology
- Priya SinghalExecutive VP & Head of Development
- Sean GodboutVP, Chief Accounting Officer & Global Corporate Controller
- Guy HadariChief Information Officer
- Tim PowerHead of Investor Relations
- Michael John PariniChief Legal Officer
- Natacha GassenbachChief Communication Officer & Head of Corporate Affairs
- Adam KeeneyExecutive VP & Head of Corporate Development
Últimas notícias sobre a Biogen
Stoke and Biogen report Dravet therapy data
United StatesBiogen launches weekly LEQEMBI IQLIK Alzheimer’s treatment in US
United StatesFDA Grants breakthrough therapy designation to Biogen’s salanersen for SMA
United StatesBiogen and UCB present positive Phase 3 PHOENYCS GO data for lupus candidate dapirolizumab pegol
United StatesFDA extends Leqembi Iqlik review timeline following major amendment
United StatesBiogen consolidates global Felzartamab rights via $850M agreement with TJ Biopharma
United States
Principais indicadores financeiros
Resultados divulgados pela Biogen, em USD.
- Cap. de mercado
- 36,1 bi
- Receita (TTM)
- 10 bi
- P/L
- 43.3
- LPA (diluído, TTM)
- 5.6
- Dividend yield
- —
- Margem de lucro
- 8.3%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 9,8 bi | 1,9 bi | 1,3 bi | |
| 9,7 bi | 2,5 bi | 1,6 bi | |
| 9,8 bi | 2,1 bi | 1,2 bi | |
| 10,2 bi | 2,9 bi | 3 bi |